Inclusion Criteria:

        General Inclusion Criteria (All Participants):

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Life expectancy of >/= 12 weeks

        Inclusion Criteria Specific to Arms A and C (R/R MM)

          -  Arm A only: Must have R/R MM for which no established therapy for MM is appropriate
             and available or be intolerant to those established therapies

          -  Arm C only: Participants with R/R MM who have received at least 3 prior lines of
             therapy.

          -  Measurable disease defined by laboratory test results.

        Inclusion Criteria Specific to Arms B and D (R/R NHL)

          -  Participants with histologically confirmed B-cell NHL who have relapsed or failed to
             respond to at least two prior systemic treatment regimens and for which no suitable
             therapy of curative intent or higher priority exists.

          -  Must have at least one bi-dimensionally measurable lesion.

        Exclusion Criteria:

        General Exclusion Criteria (All Participants)

          -  Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
             monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, hormonal therapy,
             and/or radiotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter,
             prior to initiation of study treatment

          -  Prior treatment with any anti-TIGIT agent

          -  Prior treatment with chimeric antigen receptor-T (CAR-T) therapy within 30 days before
             first study drug administration

          -  Autologous Stem-Cell Transplantation (ASCT) within 100 days prior to first study drug
             administration

          -  Active or history of autoimmune disease or immune deficiency

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at
             study enrollment, or any major episode of infection within 4 weeks prior to first
             study drug administration

        Exclusion Criteria Specific to Arms A and C (R/R MM)

          -  Primary or secondary plasma cell leukemia

          -  Current or history of CNS involvement by MM

        Exclusion Criteria Specific to Arms B and D (R/R NHL)

          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab

          -  Current or history of CNS lymphoma

          -  Current eligibility for ASCT

        Other protocol defined inclusion/exclusion criteria could apply